{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:21:21Z","timestamp":1783034481184,"version":"3.54.6"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immun Ageing"],"DOI":"10.1186\/s12979-026-00571-x","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T07:13:26Z","timestamp":1778310806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["High-dose quadrivalent influenza vaccine in older adults with or without cardiovascular risk: a meta-analysis of randomized trials on 511,890 participants"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3080-2875","authenticated-orcid":false,"given":"Mohamed S.","family":"Elgendy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-0262","authenticated-orcid":false,"given":"Abdalhakim","family":"Shubietah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5122-8200","authenticated-orcid":false,"given":"Ameer","family":"Awashra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9457-9832","authenticated-orcid":false,"given":"Mohamed","family":"Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2150-5772","authenticated-orcid":false,"given":"Mohanad","family":"Qwaider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0767-1070","authenticated-orcid":false,"given":"Mohamed A.","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0132-6455","authenticated-orcid":false,"given":"Momin A.","family":"Abuwatfa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9033-7835","authenticated-orcid":false,"given":"Mahmoud","family":"Ismayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6361-5692","authenticated-orcid":false,"given":"Mohammad","family":"Alqadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"key":"571_CR1","unstructured":"Organization WH. Influenza (seasonal). Geneva: World Health Organization; 2025. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-%28seasonal%29"},{"key":"571_CR2","unstructured":"Prevention C. for DC and. People at Increased Risk for Flu Complications. Centers for Disease Control and Prevention; 2024. Available from: https:\/\/www.cdc.gov\/flu\/highrisk\/"},{"key":"571_CR3","unstructured":"Prevention C, for DC. and. GRADE: Higher Dose and Adjuvanted Influenza Vaccines for Persons Aged\u2009\u2265\u200965 Years. Centers for Disease Control and Prevention; 2024. Available from: https:\/\/www.cdc.gov\/acip\/grade\/influenza-older-adults.html"},{"key":"571_CR4","doi-asserted-by":"publisher","unstructured":"Volpe M, Battistoni A, Gabutti G, Bonanni P, Nati G, Siliquini R. Cardiovascular disease related to influenza infection and the protective role of influenza vaccination. Int J Cardiol. 2026;448. Available from: https:\/\/doi.org\/10.1016\/j.ijcard.2026.134178","DOI":"10.1016\/j.ijcard.2026.134178"},{"key":"571_CR5","doi-asserted-by":"publisher","unstructured":"Nguyen TQ, Vlasenko D, Shetty AN, Zhao E, Reid CM, Clothier HJ et al. Systematic review and meta-analysis of respiratory viral triggers for acute myocardial infarction and stroke. Cardiovasc Res. 2025;121(9):1330\u201344. Available from: https:\/\/doi.org\/10.1093\/cvr\/cvaf092","DOI":"10.1093\/cvr\/cvaf092"},{"issue":"6","key":"571_CR6","doi-asserted-by":"publisher","first-page":"e019636","DOI":"10.1161\/JAHA.120.019636","volume":"10","author":"SH Yedlapati","year":"2021","unstructured":"Yedlapati SH, Khan SU, Talluri S, Lone AN, Khan MZ, Khan MS, et al. Effects of influenza vaccine on mortality and cardiovascular outcomes in patients with cardiovascular disease: a systematic review and meta-analysis. J Am Heart Assoc. 2021;10(6):e019636.","journal-title":"J Am Heart Assoc"},{"key":"571_CR7","doi-asserted-by":"publisher","unstructured":"Wei M, Liu L, Zhou K, Li Y. The benefits of influenza vaccination in patients with cardiovascular disease: a systematic review and meta-analysis. Front Pharmacol. 2026;Volume 16. Available from: https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/https:\/\/doi.org\/10.3389\/fphar.2025.1701127","DOI":"10.3389\/fphar.2025.1701127"},{"key":"571_CR8","doi-asserted-by":"crossref","unstructured":"Guo J, Wang T, Liu Z, Zeng W, Shen P, Sun Y et al. Estimating cardiovascular effects of influenza vaccination in older adults: a target trial emulation using proximal causal inference. eClinicalMedicine. 2025;87:103449. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2589537025003815","DOI":"10.1016\/j.eclinm.2025.103449"},{"key":"571_CR9","unstructured":"Pasteur S. Fluzone High-Dose Quadrivalent: prescribing information. U.S. Food and Drug Administration; 2019. Available from: https:\/\/www.fda.gov\/media\/132238\/download"},{"issue":"2","key":"571_CR10","doi-asserted-by":"publisher","first-page":"EVIDoa2200206","DOI":"10.1056\/EVIDoa2200206","volume":"2","author":"ND Johansen","year":"2023","unstructured":"Johansen ND, Modin D, Nealon J, Samson S, Salamand C, Loiacono MM, et al. A pragmatic randomized feasibility trial of influenza vaccines. NEJM Evid. 2023;2(2):EVIDoa2200206.","journal-title":"NEJM Evid"},{"issue":"1","key":"571_CR11","doi-asserted-by":"publisher","first-page":"106187","DOI":"10.1016\/j.jinf.2024.106187","volume":"89","author":"KG Skaarup","year":"2024","unstructured":"Skaarup KG, Lassen MCH, Modin D, Johansen ND, Loiacono MM, Harris RC, et al. The relative vaccine effectiveness of high-dose vs standard-dose influenza vaccines in preventing hospitalization and mortality: A meta-analysis of evidence from randomized trials. J Infect. 2024;89(1):106187.","journal-title":"J Infect"},{"issue":"11","key":"571_CR12","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jamacardio.2025.3460","volume":"10","author":"ND Johansen","year":"2025","unstructured":"Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, Larsen CS, et al. High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults: a prespecified secondary analysis of the DANFLU-2 randomized clinical trial. JAMA Cardiol. 2025;10(11):1186\u201394.","journal-title":"JAMA Cardiol"},{"issue":"4","key":"571_CR13","doi-asserted-by":"publisher","first-page":"e13270","DOI":"10.1111\/irv.13270","volume":"18","author":"AA Palmu","year":"2024","unstructured":"Palmu AA, Pepin S, Syrj\u00e4nen RK, Mari K, Mallett Moore T, Jokinen J, et al. High-Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults. Influenza Other Respi Viruses. 2024;18(4):e13270.","journal-title":"Influenza Other Respi Viruses"},{"issue":"23","key":"571_CR14","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1056\/NEJMoa2509834","volume":"393","author":"J Pardo-Seco","year":"2025","unstructured":"Pardo-Seco J, Rodr\u00edguez-Tenreiro-S\u00e1nchez C, Gin\u00e9-V\u00e1zquez I, Mallah N, Mir\u00e1s-Carballal S, Pi\u00f1eiro-Sotelo M, et al. High-dose influenza vaccine to reduce hospitalizations. N Engl J Med. 2025;393(23):2303\u201312.","journal-title":"N Engl J Med"},{"issue":"1","key":"571_CR15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","volume":"10","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89.","journal-title":"Syst Rev"},{"key":"571_CR16","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ WV, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024).. Cochrane; 2024. Available from: www.training.cochrane.org\/handbook"},{"key":"571_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016;5:1\u201310.","journal-title":"Syst Rev"},{"key":"571_CR18","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;l4898\u20134898.","DOI":"10.1136\/bmj.l4898"},{"issue":"7650","key":"571_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"key":"571_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12874-017-0315-7","volume":"17","author":"J Wetterslev","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17:1\u201318.","journal-title":"BMC Med Res Methodol"},{"issue":"6977","key":"571_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/bmj.310.6977.452","volume":"310","author":"RJ Cook","year":"1995","unstructured":"Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310(6977):452\u20134.","journal-title":"BMJ"},{"issue":"2","key":"571_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0197-2456(00)00134-3","volume":"22","author":"R Bender","year":"2001","unstructured":"Bender R. Calculating confidence intervals for the number needed to treat. Control Clin Trials. 2001;22(2):102\u201310.","journal-title":"Control Clin Trials"},{"key":"571_CR23","unstructured":"Johansen ND, Modin D, Pardo-Seco J, Rodriguez-Tenreiro-S\u00e1nchez C, Loiacono MM, Harris RC et al. High-Dose vs. Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults: The FLUNITY-HD Prespecified Pooled Analysis. Circulation. 2025;152(0)."},{"key":"571_CR24","doi-asserted-by":"publisher","unstructured":"Dhruva SS. Role of High-Dose Influenza Vaccine in Reducing Cardiovascular Risk. Circulation. 2026;153(11):807\u20139. Available from: https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.078657","DOI":"10.1161\/CIRCULATIONAHA.125.078657"},{"issue":"16","key":"571_CR25","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.2013.279206","volume":"310","author":"JA Udell","year":"2013","unstructured":"Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA. 2013;310(16):1711\u201320.","journal-title":"JAMA"},{"issue":"4","key":"571_CR26","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1702090","volume":"378","author":"JC Kwong","year":"2018","unstructured":"Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"571_CR27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamacardio.2019.0549","volume":"4","author":"S Kyt\u00f6maa","year":"2019","unstructured":"Kyt\u00f6maa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, et al. Association of influenza-like illness activity with hospitalizations for heart failure: the atherosclerosis risk in communities study. JAMA Cardiol. 2019;4(4):363\u20139.","journal-title":"JAMA Cardiol"},{"issue":"41","key":"571_CR28","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1093\/eurheartj\/ehaf678","volume":"46","author":"M Pareek","year":"2025","unstructured":"Pareek M, Johansen ND, Modin D, Loiacono MM, Harris RC, Dufournet M, et al. High-dose vs. standard-dose inactivated influenza vaccine and cardiovascular outcomes in persons with or without pre-existing atherosclerotic cardiovascular disease: the DANFLU-2 trial. Eur Heart J. 2025;46(41):4282\u201390.","journal-title":"Eur Heart J"},{"issue":"7","key":"571_CR29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1093\/eurheartj\/ehac737","volume":"44","author":"JA Davidson","year":"2023","unstructured":"Davidson JA, Banerjee A, Douglas I, Leyrat C, Pebody R, McDonald HI, et al. Primary prevention of acute cardiovascular events by influenza vaccination: an observational study. Eur Heart J. 2023;44(7):610\u201320.","journal-title":"Eur Heart J"},{"issue":"36","key":"571_CR30","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1093\/eurheartj\/ehaf384","volume":"46","author":"B Heidecker","year":"2025","unstructured":"Heidecker B, Libby P, Vassiliou VS, Roubille F, Vardeny O, Hassager C, et al. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement: With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute CardioVascular Care (ACVC). Eur Heart J. 2025;46(36):3518\u201331.","journal-title":"Eur Heart J"},{"issue":"21","key":"571_CR31","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.jacc.2025.07.003","volume":"86","author":"A Heidenreich","year":"2025","unstructured":"Heidenreich A, Bhatt P, Nazir A, Schaffner NT, Vardeny W. 2025 concise clinical guidance: an ACC expert consensus statement on adult immunizations as part of cardiovascular care: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025;86(21):2085\u201398.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"571_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1001\/jama.2020.23649","volume":"325","author":"O Vardeny","year":"2021","unstructured":"Vardeny O, Kim K, Udell JA, Joseph J, Desai AS, Farkouh ME, et al. Effect of high-dose trivalent vs standard-dose quadrivalent influenza vaccine on mortality or cardiopulmonary hospitalization in patients with high-risk cardiovascular disease: a randomized clinical trial. JAMA. 2021;325(1):39\u201349.","journal-title":"JAMA"},{"issue":"5","key":"571_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jval.2022.11.008","volume":"26","author":"CR Warmath","year":"2023","unstructured":"Warmath CR, Ortega-Sanchez IR, Duca LM, Porter RM, Usher MG, Bresee JS, et al. Comparisons in the health and economic assessments of using quadrivalent versus trivalent influenza vaccines: A systematic literature review. Value Heal. 2023;26(5):768\u201379.","journal-title":"Value Heal"},{"issue":"1","key":"571_CR34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2020.11.002","volume":"24","author":"F Zeevat","year":"2021","unstructured":"Zeevat F, Cr\u00e9pey P, Dolk FCK, Postma AJ, Breeveld-Dwarkasing VNA, Postma MJ. Cost-effectiveness of quadrivalent versus trivalent influenza vaccination in the Dutch National Influenza Prevention Program. Value Heal. 2021;24(1):3\u201310.","journal-title":"Value Heal"},{"issue":"8","key":"571_CR35","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3390\/vaccines10081285","volume":"10","author":"D Tavares","year":"2022","unstructured":"Tavares D, Mouri\u00f1o H, Rodr\u00edguez CA, Saborido CM. Cost effectiveness of quadrivalent versus trivalent inactivated influenza vaccines for the Portuguese elderly population. Vaccines. 2022;10(8):1285.","journal-title":"Vaccines"},{"key":"571_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/jcm11144123","volume":"11","author":"M Radovanovic","year":"2022","unstructured":"Radovanovic M, Petrovic M, Barsoum MK, Nordstrom CW, Calvin AD, Dumic I, et al. Influenza Myopericarditis and Pericarditis: A Literature Review. J Clin Med. 2022;11:14.","journal-title":"J Clin Med"}],"container-title":["Immunity &amp; Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12979-026-00571-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-026-00571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12979-026-00571-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:08:06Z","timestamp":1783033686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12979-026-00571-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["571"],"URL":"https:\/\/doi.org\/10.1186\/s12979-026-00571-x","relation":{},"ISSN":["1742-4933"],"issn-type":[{"value":"1742-4933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}